<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446276</url>
  </required_header>
  <id_info>
    <org_study_id>M-20110172A</org_study_id>
    <nct_id>NCT01446276</nct_id>
  </id_info>
  <brief_title>Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Long-term Investigation of Resveratrol on Lipid Turnover in Obese Men With Nonalcoholic Fatty Liver Disease. Effects on Liver Fat Content and Basal and Insulin Stimulated FFA and VLDL-triglyceride Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ministry of Science, Technology and Innovation, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate potential metabolic effects of resveratrol in&#xD;
      obese healthy men with non-alcoholic fatty liver disease.&#xD;
&#xD;
      The investigators hypothesize that resveratrol will:&#xD;
&#xD;
        -  decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion&#xD;
&#xD;
        -  decrease liver fat content&#xD;
&#xD;
        -  increase insulin sensitivity&#xD;
&#xD;
      The investigators will look at changes in:&#xD;
&#xD;
        -  lipid turnover (VLDL-TG kinetics, palmitate kinetics, indirect calorimetry)&#xD;
&#xD;
        -  liver fat content (MR liver spectroscopy)&#xD;
&#xD;
        -  insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp)&#xD;
&#xD;
        -  body composition (DXA and MRI)&#xD;
&#xD;
        -  lipase activity and fat cell size (fat biopsy from abdominal and femoral adipose tissue)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic VLDL-TG secretion and peripheral VLDL-TG clearance</measure>
    <time_frame>six month</time_frame>
    <description>- Changes from baseline after treatment with either resveratrol or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Basal and insulin stimulated free fatty acid (FFA) and glucose turnover</measure>
    <time_frame>six month</time_frame>
    <description>- Changes from baseline after treatment with either resveratrol or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-TG oxidation</measure>
    <time_frame>six month</time_frame>
    <description>- Changes from baseline after treatment with either resveratrol or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition (fat mass, fat-free mass, percent fat, visceral fat mass)</measure>
    <time_frame>six month</time_frame>
    <description>- Changes from baseline after treatment with either resveratrol or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipoprotein lipase activity and fat cell size in abdominal and femoral adipose tissue biopsy</measure>
    <time_frame>six months</time_frame>
    <description>- Changes from baseline after treatment with either resveratrol or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline data</measure>
    <time_frame>Baseline</time_frame>
    <description>- Comparison of baseline data between intervention group and control group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Obesity</condition>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resveratrol 500mg 3 times daily for six month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 tablet 3 times daily for six month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Men without non-alcoholic fatty liver disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>500 mg 3 times daily for six month</description>
    <arm_group_label>Resveratrol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 placebo tablet 3 times daily for six month</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  25-65 years&#xD;
&#xD;
          -  Obesity (BMI &gt; 28 kg/m2, waist/hip ratio &gt; 0,95)&#xD;
&#xD;
          -  Have nonalcoholic fatty liver disease (NAFLD)(intervention group) or do not have NAFLD&#xD;
             (control group)&#xD;
&#xD;
          -  May have hypertension and/or hypercholesterolemia&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other disease than NAFLD (e.g. diabetes, thyroid or parathyroid disease, heart,&#xD;
             liver or kidney disease)&#xD;
&#xD;
          -  Present and previous malignancy&#xD;
&#xD;
          -  Alcohol dependency (more than 21 units of alcohol per week)&#xD;
&#xD;
          -  History of smoking&#xD;
&#xD;
          -  Participation in studies with radioactive isotopes within the last six months&#xD;
&#xD;
          -  Hemoglobin under normal range regarding to sex (under 8.3 mmol/l for men)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SÃ¸ren Nielsen, MD, associate professor, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Endocrinology and Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology and Internal Medicine</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>October 3, 2011</study_first_submitted>
  <study_first_submitted_qc>October 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <last_update_submitted>April 25, 2014</last_update_submitted>
  <last_update_submitted_qc>April 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Resveratrol</keyword>
  <keyword>Nonalcoholic fatty liver disease</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Lipid turnover</keyword>
  <keyword>Liver fat content</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

